ANVS - PRISM Mid-Day Movers: FDA Progress and Global Health Approvals Boost Indices

2025-06-24 14:00:35 ET

Capricor Therapeutics Rises 18% on FDA Progress for Duchenne Cell Therapy
Capricor Therapeutics, Inc. ( CAPR ) jumped 18.23% to lead the PRISM Emerging Biotech Index after providing a regulatory update on its Biologics License Application (BLA) for Deramiocel , its lead cell therapy for Duchenne Muscular Dystrophy (DMD). The FDA has confirmed that an Advisory Committee meeting is not required at this time, and the BLA remains under Priority Review with a PDUFA target action date of August 31, 2025. Four-year data presented at the PPMD 2025 Conference demonstrated sustained cardiac function from long-term Deramiocel treatment.

Trinity Biotech Surges 20% Following WHO Approval for HIV Test Manufacturing Shift
Trinity Biotech plc ( TRIB ) rose 20.49%, lifting the PRISM Emerging Global Health Index , after announcing World Health Organization approval for offshoring and outsourcing manufacturing of its flagship TrinScreen(TM) HIV test . The transition is expected to enhance gross margins, free up working capital, and drive scalability as part of Trinity's broader transformation plan.

Other PRISM Mid-Day Movers:
? Houston American Energy Corp. ( HUSA ) down 34.58%
? iBio, Inc . ( IBIO ) up 20.71%
? Annovis Bio, Inc. ( ANVS ) up 17.05%
? BigBear.ai Holdings, Inc. ( BBAI ) up 18.56%

The post PRISM Mid-Day Movers: FDA Progress and Global Health Approvals Boost Indices appeared first on PRISM MarketView .

COMTEX_466629306/2927/2025-06-24T13:00:35